Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim prophylaxis during concurrent chemoradiotherapy for cervical cancer
ChiCTR1900021410Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in Cervical Cancer (CC), sponsored by Chinese PLA General Hospital. Primary endpoint: Incidence of grade III/IV neutropenia in each chemotherapy cycle. Started Feb 2019; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900021410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021410.